Activation of Lung p53 by Nutlin-3a Prevents and Reverses Experimental Pulmonary Hypertension
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background—: Induction of cellular senescence through activation of the p53 tumor suppressor protein is a new option for treating proliferative disorders. Nutlins prevent the ubiquitin ligase MDM2 (murine double minute 2), a negative p53 regulator, from interacting with p53. We hypothesized that cell senescence induced by Nutlin-3a exerted therapeutic effects in pulmonary hypertension (PH) by limiting the proliferation of pulmonary artery smooth muscle cells (PA-SMCs). Methods and Results—: Nutlin-3a treatment of cultured human PA-SMCs resulted in cell growth arrest with the induction of senescence but not apoptosis; increased phosphorylated p53 protein levels; and expression of p53 target genes including p21, Bax, BTG2, and MDM2. Daily intraperitoneal Nutlin-3a treatment for 3 weeks dose-dependently reduced PH, right ventricular hypertrophy, and distal pulmonary artery muscularization in mice exposed to chronic hypoxia or SU5416/hypoxia. Nutlin-3a treatment also partially reversed PH in chronically hypoxic or transgenic mice overexpressing the serotonin-transporter in SMCs (SM22-5HTT+ mice). In these mouse models of PH, Nutlin-3a markedly increased senescent p21-stained PA-SMCs; lung p53, p21, and MDM2 protein levels; and p21, Bax, PUMA, BTG2, and MDM2 mRNA levels; but induced only minor changes in control mice without PH. Marked MDM2 immunostaining was seen in both mouse and human remodeled pulmonary vessels, supporting the use of Nutlins as a PH-targeted therapy. PH prevention or reversal by Nutlin-3a required lung p53 stabilization and increased p21 expression, as indicated by the absence of Nutlin-3a effects in hypoxia-exposed p53 −/− and p21 −/− mice. Conclusions—: Nutlin-3a may hold promise as a prosenescence treatment targeting PA-SMCs in PH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 2×
“Nutlins are cis-imidazoline analogs recently developed as anticancer agents.(13) These selective small-molecule p53-MDM2 binding inhibitors stabilize p53, thereby increasing the expression of genes targeted by p53 including the antiproliferative gene BTG2, the prosenescent gene p21, and the proapoptotic genes Bax and…”
BackgroundClearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670 · cited 2×
“Whether this may occur in response to Nutlin treatment may depend on various factors such as age, immune system performance, and environmental conditions.(38) Thus, inducing cell senescence might hold promise as a treatment against pulmonary vascular remodeling, provided the senescent cells are simultaneously cleared…”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“Also common is posttranslational p53 inactivation via interaction of the p53 protein with its negative regulator MDM2 (murine double minute 2), a specific p53 ubiquitin ligase and transcriptional inhibitor.(10,11) MDM2 is overexpressed in many human tumors, suggesting that p53-MDM2 interactions may hold promise as a t…”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379 · cited 3×
“Among the transcriptional targets of p53, p21 has been shown to play a major role as a regulator of cell-cycle progression and to be involved in cell senescence.(36) We found that the protective action of Nutlin-3a against PH required p21, as indicated by the inability of Nutlin-3a to prevent chronic hypoxia-induced P…”
BackgroundTP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes
Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · cited 1×
“The dissimilar effects of Nutlin-3a in hypoxic versus normoxic mice are also consistent with previous studies showing that systemic Nutlin treatment is toxic to tumor tissue but not to normal tissue.(31,32) Because previous studies reported that p53 activation could lead to heart failure,(33) we measured p53 protein l…”
ResultThe p53 orchestra: Mdm2 and Mdmx set the tone
Wade, M., Wang, Y. V., & Wahl, G. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.01.009 · Cited by 450
Pro-senescence therapy for cancer treatment
Nardella, C., Clohessy, J. G., Alimonti, A., & Pandolfi, P. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3057 · Cited by 437
Alimonti, A., Nardella, C., Chen, Z., Clohessy, J. G., Carracedo, A., Trotman, L. C., Cheng, K., Varmeh, S., Kozma, S. C., Thomas, G., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40535 · Cited by 374
Noureddine, H., Gary-Bobo, G., Alifano, M., Marcos, E., Saker, M., Vienney, N., Amsellem, V., Maitre, B., Chaouat, A., Chouaid, C., et al. (2011) · Circulation Research · doi:10.1161/circresaha.111.241299 · Cited by 173 · cited 4×
“In these previous studies, we showed that the accumulation of senescent cells within pulmonary vessels contributed to neointima formation in patients with chronic lung diseases.(24) Indeed, senescent cells are still metabolically active and release various factors, including cytokines, growth factors, and matrix compo…”
BackgroundInfluentialSelf-citationEfeyan, A., Ortega-Molina, A., Velasco-Miguel, S., Herranz, D., Vassilev, L. T., & Serrano, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0200 · Cited by 140 · cited 1×
“However, PA-SMCs treated with Nutlin-3a did not become apoptotic, a finding consistent with results obtained using other cell types, including fibroblasts from mice and humans.(20,21) Chronic Nutlin-3a treatment of mice during hypoxia exposure considerably attenuated PH severity by decreasing MDM2 α-SMA Hoechst Merge”
Result
Research works printed but not linked: 27
- 10.1016/j.jacc.2009.04.018 · DOI · Paper page
- 10.1172/JCI200112805 · DOI
- 10.1161/01.RES.88.1.e2 · DOI · Paper page
- 10.1172/JCI1910 · DOI
- 10.1161/circulationaha.105.591321 · DOI · Paper page
- 10.1161/01.cir.0000012754.72951.3d · DOI · Paper page
- 10.1172/JCI23203 · DOI · Paper page
- 10.1172/JCI24838 · DOI · Paper page
- 10.1016/S0968-0004(02)02166-7 · DOI · Paper page
- 10.1016/S0065-230X(03)01001-7 · DOI
- 10.1242/jcs.03293 · DOI · Paper page
- 10.1093/cvr/cvr108 · DOI
- 10.1002/(SICI)1096-9896(199807)185:3<303::AID-PATH106>3.0.CO;2-P · DOI · Paper page
- 10.2353/ajpath.2006.051351 · DOI
- 10.1038/32925 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-2780 · DOI · Paper page
- 10.1158/1541-7786.MCR-09-0144 · DOI
- 10.1158/1078-0432.CCR-08-2955 · DOI · Paper page
- 10.1164/rccm.201103-0412OC · DOI · Paper page
- 10.1161/01.res.0000222546.45372.a0 · DOI · Paper page
- 10.1161/circulationaha.110.973750 · DOI
- 10.1152/ajplung.00286.2010 · DOI
- Lane DP, Brown CJ, Verma C, Cheok CF. New insights into p53 based therapy. Discov Med. 2011;12:107–117.
- 10.1038/nature05602 · DOI · Paper page
- 10.1152/ajprenal.00230.2007 · DOI · Paper page
- Meek DW, Knippschild U. Posttranslational modification of MDM2. Mol Cancer Res. 2003;1:1017–1026.
- 10.1164/rccm.201105-0802OC · DOI · Paper page
Cited by
Cellular senescence: from physiology to pathology
Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
“, using corticosteroids [368], beta-interferons [370] or DNA-damaging chemotherapeutics in MS, practices that may prove detrimental in the long run.”
BackgroundSenescence and senotherapeutics: a new field in cancer therapy
Myrianthopoulos, V., Evangelou, K., Vasileiou, P. V. S., Cooks, T., Vassilakopoulos, T. P., Pangalis, G. A., Kouloukoussa, M., Kittas, C., Georgakilas, A. G., & Gorgoulis, V. G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.006 · Cited by 160
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
Born, E., Lipskaia, L., Breau, M., Houssaini, A., Beaulieu, D., Marcos, E., Pierre, R., Do Cruzeiro, M., Lefevre, M., Derumeaux, G., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.058794 · Cited by 148
Self-citation
Metadata
- Authors
- Mouraret, N., Marcos, E., Abid, S., Gary-Bobo, G., Saker, M., Houssaini, A., Dubois-Rande, J.-L., Boyer, L., Boczkowski, J., Derumeaux, G., Amsellem, V., & Adnot, S.
- Venue
- Circulation
- Published
- 2013-04-23
- Volume
- 127
- Issue
- 16
- Pages
- 1664-1676
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2045039711
- Cited by
- 123
- References
- 11
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.